跳至主要内容
临床试验/CTRI/2024/11/076491
CTRI/2024/11/076491尚未招募4 期

Evaluate the effect of punarnava arka in simple allergic conjunctivitis - a randomised controlled clinical trial

Dr Mahore Akash Manohar1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年1月15日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
The results of reduction in signs and symptoms

研究概览

简要总结

Need for the study :

A type 1 hypersensitivity reaction to exogenous allergens in the atmosphere is simple allergic conjunctivitis. The estimated prevalence is 12.22%. Males are more likely to experience it (13.44%) than females (10.71%). The most frequent precipitating trigger was dust (35%) and the most common condition was persistent conjunctivitis (54.8%). There is no known unique aetiology for this moderate, non-specific inflammation of the conjunctiva, which presents with symptoms of increased lacrimation, itching, redness, and oedema. Since there is typically no cure for this illness, care is centred on symptom control and avoiding situations that exacerbate symptoms.

Punarnava is Shothahara and known for its anti-inflammatory action, Antimicrobial properties, Analgesic and Antioxidant activities so it may be brought in practice in the form of ArkaPunarnava arkais selected keeping in view to prove its efficacy in management of simple allergic conjunctivitis.

Aim :

Effect of PUNARNAVA ARKA in Simple Allergic Conjunctivitis

Objectives: To evaluate the effect of PUNARNAVA ARKA in Simple Allergic Conjunctivitis

To compare the effect of Punarnava Arka with control drug.

Research question :Is Effect of PUNARNAVA ARKA and Olopatadine Hydrochloride Ophthalmic Solution Ip 0.1% comparable in the management of simple allergic conjunctivitis?

Hypothesis: H0 – Effect of Punarnava Arka is not comparablein Simple Allergic Conjunctivitis

H1 – Effect of Punarnava Arka is comparable in Simple Allergic Conjunctivitis

Expected Outcome –The results of PUNARNAVA ARKA and Eyedrop Olopatadine Hydrochloride Ophthalmic Solution Ip 0.1% are comparable.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
All

入选标准

  • Patients presenting with signs and symptoms of Simple Allergic Conjunctivitis and fulfilling the diagnostic criteria.

排除标准

  • Patients suffering from other forms Allergic Conjunctivitis like Keratoconjunctivitis sicca Atopic keratoconjunctivitis Giant papillary conjunctivitis drug or material sensitivity etc Patients having severe conditions of ocular surface disorders Patients having complicated eye diseases like Trachoma Trichiasis Steven Johnson syndrome Synechiae etc will be excluded Patient suffering from bacterial viral chlamydial, parasitic and all other types of conjunctivitis (contagious & non contagious) Patients suffering from corneal ulcers opacities trauma foreign bodies OSD etc Conjunctival epitheliopathies like Pterygium Pseudo-pterygium Tumours Retention cysts Diagnosed cases of Glaucoma retinopathies optic neuritis dry eye and who are under long term topical ocular drug therapies for any ophthalmic infective conditions Extremely debilitated patients pregnant ladies those who are working with on screen professions Specific systemic disorders like Renal pathologies Uncontrolled Diabetes Hypertension and Hyperlipidaemia Cardiovascular diseases etc.

结局指标

主要结局

The results of reduction in signs and symptoms

时间窗: DAY 0th(Before Treatment) | DAY 21(After Treatment) | DAY 36(Follow Up)

of itching, redness, watering and oedema by Punarnava Arka and Eyedrop Olopatadine Hydrochloride ophthalmic soltion IP 0.1 percent are comparable.

时间窗: DAY 0th(Before Treatment) | DAY 21(After Treatment) | DAY 36(Follow Up)

次要结局

未报告次要终点

研究者

发起方
Dr Mahore Akash Manohar
申办方类型
Other [(self)]
责任方
Principal Investigator
主要研究者

Dr Mahore Akash Manohar

KAHERs Shri BMK Ayurveda Mahavidyalaya, Shahapur, BELAGAVI, Karnataka, INDIA

研究点 (1)

Loading locations...

相似试验